The
The federal agency said it's restricting the vaccine because of the risk of thrombosis with thrombocytopenia syndrome, which can cause rare but potentially life-threatening blood clots and low levels of blood platelets about one to two weeks after the administration of the shot.
Despite the risks, the FDA said the known and potential benefits of the
"We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in
The FDA temporarily paused the administration of the Johnson & Johnson COVID-19 vaccine last year after several reported cases of blood clotting. At the time, all six cases were found in women between the ages of 18 and 48. At least one died.
Copyright 2022 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source